1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
- Resource Type
- Abstract
- Source
- In
Annals of Oncology September 2020 31 Supplement 4:S887-S887 - Subject
- Language
- ISSN
- 0923-7534